Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DUVOID vs MYOTONACHOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective alpha-1A adrenergic receptor antagonist; relaxes smooth muscle in the bladder neck and prostate, reducing outflow resistance.
Myotonachol (bethanechol chloride) is a direct-acting parasympathomimetic agent that selectively stimulates muscarinic acetylcholine receptors, particularly M3 subtypes, in smooth muscle of the gastrointestinal tract and urinary bladder. It mimics the action of acetylcholine but is resistant to hydrolysis by acetylcholinesterase, leading to increased smooth muscle tone and peristalsis.
Benign prostatic hyperplasia (BPH) - treatment of symptoms,Off-label: None established
FDA-approved: Treatment of acute postoperative and postpartum nonobstructive urinary retention and neurogenic atony of the bladder.,Off-label: Treatment of gastroesophageal reflux disease; management of chronic intestinal pseudo-obstruction; treatment of xerostomia (dry mouth) in Sjögren's syndrome or radiation-induced.
100 mg orally three times daily.
25 mg orally three times daily. Maximum dose 100 mg four times daily.
Terminal elimination half-life is 12–15 hours in patients with normal renal function; prolonged to 24 hours or more in moderate-to-severe renal impairment.
Terminal elimination half-life: 1.5-2.5 hours (prolonged in renal impairment).
Extensively metabolized in the liver primarily by CYP2D6 and CYP3A4, with possible minor contributions from other CYPs.
Bethanechol is primarily metabolized via hydrolysis by plasma esterases (pseudocholinesterases) to inactive metabolites. Minimal hepatic metabolism occurs.
Renal elimination accounts for approximately 90% of a dose as unchanged drug; biliary/fecal excretion is minor (<10%).
Renal: 70-80% unchanged; biliary/fecal: 20-30% as metabolites.
Approximately 50–70% bound to plasma proteins, primarily albumin.
~30%, bound primarily to albumin.
Vd approximately 0.6 L/kg, indicating distribution into total body water.
0.3-0.6 L/kg, indicating distribution into total body water.
Oral: 75–85% (may be decreased with food); subcutaneous: nearly 100%.
Oral: 10-20% (extensive first-pass metabolism); Subcutaneous: ~80%; Intravenous: 100%.
GFR 30-89 m L/min: no adjustment; GFR <30 m L/min: avoid use.
GFR 30-59 m L/min: 25 mg twice daily. GFR 15-29 m L/min: 25 mg once daily. GFR <15 m L/min: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 50 mg twice daily; Child-Pugh C: avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: 25 mg twice daily. Child-Pugh C: not recommended.
Not recommended for use in pediatric patients.
0.5-1 mg/kg orally three times daily; maximum 25 mg per dose.
Initial dose 50 mg twice daily; titrate cautiously due to increased anticholinergic sensitivity.
Start at 25 mg twice daily due to increased anticholinergic sensitivity.
None.
None
Orthostatic hypotension (especially dose-related; syncope reported),Intraoperative floppy iris syndrome (IFIS) during cataract surgery,Priapism (rare),Dizziness, somnolence, and fatigue may occur,Use caution with hepatic impairment,Avoid use with strong CYP3A4 inhibitors or inducers
May cause reflex tachycardia due to hypotension; caution in patients with coronary artery disease, bradycardia, or recent myocardial infarction. Increased vagal tone may precipitate asthma attacks; avoid in asthmatics. May cause exacerbation of peptic ulcer disease. Can increase ureteral pressure; avoid in ureteral obstruction. Use cautiously in patients with epilepsy or hyperthyroidism. Monitor for cholinergic crisis (salivation, lacrimation, urination, defecation, emesis).
Hypersensitivity to DUVOID or any component,Moderate to severe hepatic impairment (Child-Pugh class B or C),Use with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir)
Absolute: Hypersensitivity to bethanechol; mechanical obstruction of the gastrointestinal or urinary tract; recent gastrointestinal anastomosis or bladder surgery; hyperthyroidism; peptic ulcer disease; asthma; epilepsy; Parkinsonism; hypotension; bradycardia; coronary artery disease. Relative: Pregnancy (C); nursing mothers; patients with vagotonia or receiving quinidine or procainamide.
Take on an empty stomach; food may decrease absorption. Avoid alcohol as it may increase cholinergic side effects.
Food decreases absorption; take on an empty stomach. Avoid high-fat meals as they may increase side effects. No known specific food interactions.
DUVOID (bethanechol) is classified as FDA Pregnancy Category C. No adequate studies in pregnant women. Animal reproduction studies have not been conducted. Fetal risk cannot be ruled out. Use only if potential benefit justifies potential risk to fetus. No known specific trimester risks.
Pregnancy Category C. First trimester: Animal studies show fetal resorption and skeletal anomalies at doses 2-3 times the maximum recommended human dose. No adequate human studies. Second trimester: Potential for premature labor due to cholinergic stimulation. Third trimester: Increased risk of uterine hyperstimulation and fetal distress if used for labor induction. Avoid use during pregnancy unless clearly needed.
It is not known whether bethanechol is excreted in human milk. Caution should be exercised when administered to a nursing woman. M/P ratio is unknown.
Excreted in human milk in low concentrations. M/P ratio not established. Caution advised. Potential for cholinergic adverse effects in the infant (e.g., diarrhea, increased secretions). Use only if benefit outweighs risk.
No formal pharmacokinetic studies in pregnancy. Due to increased plasma volume and renal clearance, dose adjustments may be necessary but specific recommendations are lacking. Use lowest effective dose and monitor clinical response.
No standard dose adjustments recommended due to limited pharmacokinetic data in pregnancy. However, increased plasma volume and renal clearance may necessitate dose titration based on clinical response. Use lowest effective dose and monitor for maternal cholinergic toxicity.
DUVOID (bethanechol) is a cholinergic agonist used for urinary retention. Monitor for cholinergic crisis (excessive salivation, sweating, bradycardia). Administer on an empty stomach to reduce GI upset. Avoid in patients with asthma, hyperthyroidism, peptic ulcer disease, or epilepsy. Atropine is the antidote for overdose.
MYOTONACHOL (bethanechol) is a cholinergic agonist used for urinary retention. Monitor for bradycardia and bronchospasm, especially in patients with asthma or cardiac disease. Administer on an empty stomach to reduce nausea. Avoid use in patients with GI obstruction or recent bladder surgery. Atropine should be readily available as an antidote.
Take this medication on an empty stomach, 1 hour before or 2 hours after meals.,Report any signs of excessive sweating, salivation, or bradycardia to your healthcare provider.,Avoid driving or operating machinery until you know how this drug affects you.,Do not stop taking this medication abruptly; consult your doctor for dose adjustments.,Keep a list of all medications you take and share with your healthcare provider.
Take this medication on an empty stomach, 1 hour before or 2 hours after meals.,Avoid alcohol and caffeine, as they may worsen side effects.,Report symptoms like slow heart rate, wheezing, dizziness, or excessive sweating.,Do not drive or operate heavy machinery until you know how this drug affects you.,If you miss a dose, skip it and take the next dose at the regular time; do not double the dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DUVOID vs MYOTONACHOL, answered by our medical review team.
DUVOID is a Cholinergic Agonist that works by Selective alpha-1A adrenergic receptor antagonist; relaxes smooth muscle in the bladder neck and prostate, reducing outflow resistance.. MYOTONACHOL is a Cholinergic Agonist that works by Myotonachol (bethanechol chloride) is a direct-acting parasympathomimetic agent that selectively stimulates muscarinic acetylcholine receptors, particularly M3 subtypes, in smooth muscle of the gastrointestinal tract and urinary bladder. It mimics the action of acetylcholine but is resistant to hydrolysis by acetylcholinesterase, leading to increased smooth muscle tone and peristalsis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DUVOID and MYOTONACHOL depend on the specific clinical indication. These are both Cholinergic Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DUVOID is: 100 mg orally three times daily.. The standard adult dose of MYOTONACHOL is: 25 mg orally three times daily. Maximum dose 100 mg four times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DUVOID and MYOTONACHOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DUVOID is classified as Category C. DUVOID (bethanechol) is classified as FDA Pregnancy Category C. No adequate studies in pregnant women. Animal reproduction studies have not been conducted. Fetal risk cannot be rul. MYOTONACHOL is classified as Category C. Pregnancy Category C. First trimester: Animal studies show fetal resorption and skeletal anomalies at doses 2-3 times the maximum recommended human dose. No adequate human studies.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.